Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease : retrospective analysis of 158 cases from the French registry

• Published in: Bone marrow transplantation (Basingstoke) Vol. 21; no. 8; pp. 787 - 793
• Main Authors: MOREAU, P, FLEURY, J, LAMY, T, LOTZ, J. P, MUNCK, J. N, DIVINE, M, FERME, C, PENY, A. M, FRUCHART, C, ORIOL, P, OJEDA, M, REMAN, O, BRICE, P, MILPIED, N, GISSELBRECHT, C, LEGROS, M, HAROUSSEAU, J. L, COLOMBAT, P, BOUABDALLAH, R, LIOURE, B, VOILLAT, L, CASASNOVAS, O, FRANCOIS, S, SADOUN, A
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 01.04.1998
• Subjects: Adolescent; Adult; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Autografts; Biological and medical sciences; Bone marrow, stem cells transplantation. Graft versus host reaction; Clinical trials; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease - mortality; Hodgkin Disease - therapy; Humans; Male; Medical sciences; Middle Aged; Neoplasms, Second Primary - etiology; Patients; Prognosis; Remission; Retrospective Studies; Risk; Stem cell transplantation; Stem cells; Survival; Survival Rate; Toxicity; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Transplantation; Transplantation, Autologous; Human; Prognosis; Stem cell; Hematopoietic cell; Hodgkin disease; Malignant hemopathy; Lymphoma; Blood; Autograft; Treatment; Second cancer; Lymphoproliferative syndrome; Bone marrow; Engraftment; Complication; Graft; Early; Advanced stage
• ISSN: 0268-3369; 1476-5365
• DOI: 10.1038/sj.bmt.1701174

This retrospective study was undertaken to evaluate cure rates, toxicity and late effects of early intensive therapy followed by autologous stem cell transplantation (ASCT) in patients with advanced Hodgkin's disease (HD). One hundred and fifty-eight cases of ASCT registered in the French database (SFGM) were retrospectively analyzed. Disease status at the time of ASCT was first partial response (PR) in 85, first complete remission (CR1) in 45 or primary refractory in 28 cases. The median time interval between diagnosis and ASCT was 7 months (range 4-13). At the time of analysis in December 1995, 121/158 patients (76.6%) were alive, including 111 (70.2%) in continuous CR with a median follow-up for surviving patients of 46 months (range 8-123). Peri-ASCT toxic death rate was 3%, and the actuarial risk of new malignancies was 4.9% at 5 years. The cumulative probability of 5-year overall survival (OS) was 75.2% for the entire group of patients, 80.6% for the chemosensitive ones, and 33.9% for the primary refractory (chemosensitive vs refractory, P < 0.0001). The cumulative probability of 5-year event-free survival (EFS) was 66.1% for the entire group of patients, 73.7% for the chemosensitive ones, and 26.1% for the primary refractory (chemosensitive vs refractory, P < 0.0001). The only significant prognostic factor for both OS and EFS was disease status at the time of ASCT. Early ASCT in advanced HD is feasible, with a low risk of toxicity and without a higher rate of late effects compared with conventional treatment. Results achieved in chemosensitive patients at the time of transplantation lay the basis of future prospective randomized trials comparing ACST as front-line treatment to conventional treatment in high-risk cases.